Clinical trials
Completed Leukemia trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
82 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 6 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 4 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 82 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 9 |
| European Organisation for Research and Treatment of Cancer - EORTC | 7 |
| Bristol-Myers Squibb | 4 |
| Institut Paoli-Calmettes | 4 |
| Amgen Research (Munich) GmbH | 3 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Daiichi Sankyo | 3 |
| University Hospital, Bordeaux | 3 |
| AbbVie | 2 |
| Amgen | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia | 82 |
| Leukemia, Myeloid, Acute | 21 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 14 |
| Lymphoma | 14 |
| Recurrence | 12 |
| Neoplasms | 11 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 9 |
| Congenital Abnormalities | 8 |
| Hematologic Diseases | 8 |
Trials
Showing 1 to 25 of 82. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.